Patents by Inventor Robert W. Clarke
Robert W. Clarke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180153996Abstract: The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.Type: ApplicationFiled: September 29, 2017Publication date: June 7, 2018Inventors: Michael M. Lipp, Jean C. Sung, Robert W. Clarke, David L. Hava
-
Patent number: 9233158Abstract: The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.Type: GrantFiled: May 20, 2015Date of Patent: January 12, 2016Assignee: Pulmatrix, Inc.Inventors: Michael M. Lipp, Jean C. Sung, Robert W. Clarke, David L. Hava
-
Publication number: 20150250875Abstract: The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.Type: ApplicationFiled: May 20, 2015Publication date: September 10, 2015Inventors: Michael M. Lipp, Jean C. Sung, Robert W. Clarke, David L. Hava
-
Publication number: 20150196589Abstract: Conductive formulations containing conductive agents, such as salts, ionic surfactants, or other substances that are in an ionized state or easily ionized in an aqueous or organic solvent environment, and methods of use, have been developed. One or more active agents, such as antivirals, antimicrobials, anti-inflammatories, proteins or peptides, may optionally be included with the formulation. The active agent may be administered with or incorporated into the formulation, or may be administered after the conductive formulation is administered. When applied to mucosal lining fluids, the formulation alters the physical properties such as the surface tension, surface elasticity, and bulk viscosity of the mucosal lining. The formulation is administered in an amount sufficient to alter biophysical properties in the mucosal linings of the body.Type: ApplicationFiled: November 14, 2014Publication date: July 16, 2015Inventors: Wiwik S. WATANABE, Matthew THOMAS, Jeffrey P. KATSTRA, Robert W. CLARKE
-
Publication number: 20150079173Abstract: Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.Type: ApplicationFiled: October 21, 2013Publication date: March 19, 2015Applicant: PULMATRIX, INC.Inventors: David A. EDWARDS, Jonathan Chun-Wah MAN, Jeffrey P. KATSTRA, Robert W. CLARKE
-
Publication number: 20140134251Abstract: The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca+2 to Na+ is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.Type: ApplicationFiled: October 23, 2013Publication date: May 15, 2014Applicant: PULMATRIX, INC.Inventors: Michael M. LIPP, Robert W. CLARKE, David L. HAVA, Richard BATYCKY, John HANRAHAN
-
Patent number: 8591866Abstract: Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.Type: GrantFiled: April 25, 2012Date of Patent: November 26, 2013Assignee: Pulmatrix, Inc.Inventors: David A. Edwards, Jonathan Chun-Wah Man, Jeffrey P. Katstra, Robert W. Clarke
-
Publication number: 20130281361Abstract: The present invention relates to methods of treating or preventing non-enveloped viral infection and/or disease caused by non-enveloped virus infection, particularly a viral infection caused by rhino virus. The methods comprise administering to an individual in need thereof an effective amount of a defensin peptide. The defensin peptide may be selected from ?-, ?-, or ?-defensins.Type: ApplicationFiled: November 4, 2011Publication date: October 24, 2013Applicant: PULMATRIX, INC.Inventors: David L. Hava, Robert W. Clarke
-
Publication number: 20130213398Abstract: The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.Type: ApplicationFiled: August 26, 2011Publication date: August 22, 2013Inventors: Michael M. Lipp, Jean C. Sung, Robert W. Clarke, David L. Hava
-
Publication number: 20130203715Abstract: Methods are described for treating or preventing a respiratory infection by administering an effective amount of a TRP channel agonist.Type: ApplicationFiled: July 20, 2011Publication date: August 8, 2013Applicant: Pulmatrix, Inc.Inventors: David L. Hava, Robert W. Clarke
-
Publication number: 20130164338Abstract: The invention relates to a methods for treating cystic fibrosis, comprising administering an effective amount of a calcium salt formulation to the respiratory tract of an individual with cystic fibrosis. The calcium salt formulation is can be a dry powder formulation.Type: ApplicationFiled: August 26, 2011Publication date: June 27, 2013Applicant: Pulmatrix, Inc.Inventors: Michael M. Lipp, Robert W. Clarke, David L. Hava
-
Publication number: 20130078282Abstract: Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.Type: ApplicationFiled: April 25, 2012Publication date: March 28, 2013Applicant: Pulmatrix, Inc.Inventors: David A. Edwards, Jonathan C. Man, Jeffrey P. Katstra, Robert W. Clarke
-
Patent number: 8187637Abstract: Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.Type: GrantFiled: March 6, 2007Date of Patent: May 29, 2012Assignee: Pulmatrix, Inc.Inventors: David A. Edwards, Jonathan C. Man, Jeffrey P. Katstra, Robert W. Clarke
-
Publication number: 20120107414Abstract: The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca+2 to Na+ is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.Type: ApplicationFiled: March 26, 2010Publication date: May 3, 2012Applicant: Pulmatrix, Inc.Inventors: Michael M. Lipp, Robert W. Clarke, David L. Hava, Richard Batycky, John Hanrahan
-
Publication number: 20120083531Abstract: The present invention relates to pharmaceutical compositions suitable for inhalation, comprising as an active ingredient calcium lactate or calcium citrate. The invention also relates to methods of treating, preventing, and reducing the spread of an infection of the respiratory tract, comprising administering a pharmaceutical composition that comprises calcium lactate or calcium citrate as an active ingredient.Type: ApplicationFiled: March 26, 2010Publication date: April 5, 2012Inventors: Robert W. Clarke, Richard Batycky, David L. Hava, Michal M. Lipp
-
Publication number: 20120070417Abstract: The invention relates to pharmaceutical compositions that contain a calcium salt as an active ingredient and also comprise another anti-influenza agent, and to methods for treating or preventing influenza virus infection.Type: ApplicationFiled: March 26, 2010Publication date: March 22, 2012Applicant: PULMATRIX, INC.Inventors: Richard Batycky, David L. Hava, Robert W. Clarke, Michal M. Lipp
-
Publication number: 20120058198Abstract: The invention relates to methods for treating bacterial infection of the respiratory tract, including pneumonias, such as ventilator-associated pneumonia, and to methods for treating ventilator-associated tracheobronchitis, comprising administering an effective amount of a salt formulation as an aerosol to the respiratory tract of an individual in need thereof. The formulations can also be used to reduce transmission of pathogen which can infect the respiratory tract, cause pneumonia or cause ventilator-associated tracheobronchitis.Type: ApplicationFiled: March 26, 2010Publication date: March 8, 2012Applicant: PULMATRIX, INC.Inventors: Robert W. Clarke, Richard Batycky, Wesley H. Dehaan, David L. Hava, Michael M. Lipp, John Hanrahan
-
Publication number: 20110190096Abstract: The invention relates to a stretching apparatus which is used to stretch the posterior muscles and tendons by means of powered stretching movements. The apparatus comprises a body (102), a seat area (101) a moveable handle grip (111) and foot pedals (105). In use grips (111) are moved forward whilst the user keeps his or her legs straight. That movement stretches some of the posterior muscles (including the back and buttock muscles). Further movement of the foot pedals 105 toward the user stretches his or her upper and lower leg muscles. The stretching movements could be mechanical, e.g. spring or worm screw actuated, or other power could be used. Electronic control (120) of the apparatus is described.Type: ApplicationFiled: June 12, 2009Publication date: August 4, 2011Applicant: Sportfit LimitedInventor: Robert W. Clarke
-
Patent number: 4284217Abstract: An inflatable ball is carried on a bicycle by a carrying device which has a holder releasably engaging the bicycle handlebar and a stem projecting from the holder into the valve of the ball and grippingly engaging a wall of the valve within the interior of the ball.Type: GrantFiled: January 21, 1980Date of Patent: August 18, 1981Inventors: James J. Johnston, Robert W. Clarke
-
Patent number: 4195215Abstract: The specification discloses methods of joining two or more metal members together by combinations of innovative sealants, welding and/or cure heat. More particularly, it relates to methods and materials for improving the sealing, welding, and spacing of metal parts by combining adhesive sealants, fluxes, and metallic beads of discrete shape, size, and composition; and further, by novel organization of such components into weldable seals of simple or complex shape; and further, by magnetically treating such combinations to permit the application of wet or dry forms of the weldable sealant in self-retained-in-place locations while awaiting further assembly operations; and further, to utilize combinations of such components so that they can be handled dry prior to and during joining of the metal parts, with cure initiating as a result of weld heat, completed where necessary in subsequent production stages such as in automotive paint-drying operations.Type: GrantFiled: October 13, 1978Date of Patent: March 25, 1980Inventor: Robert W. Clarke